CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...